DoseRoutine supplement library logoDoseRoutine
Atomoxetine capsules photographed on a matte clinical surface
DoseRoutine Atomoxetine — Atomoxetine capsules photographed on a matte clinical surface. Original DoseRoutine photography.
medicationPrescription only (US)Approved by the FDA as Strattera for ADHD in children, adolescents, and adults, and carries a boxed warning about suicidal ideation in pediatric patientsNot a stimulant and not federally scheduled, unlike most other ADHD medications

AtomoxetineBenefits, Dosage & Interactions

Also known as: Strattera

Atomoxetine, sold as Strattera, is a selective norepinephrine reuptake inhibitor approved for ADHD in children, adolescents and adults. It is typically taken in the morning. The reported plasma half-life is about 5 hours, which shapes dosing frequency. Dose, response, and interaction risk vary by individual, so use should be reviewed with a clinician.

How much Atomoxetine do people take?

Adult ADHD trials titrated atomoxetine up to roughly 80–120 mg/day, most often reached via a starting dose near 40 mg/day. Route reported: Oral capsule. Frequency reported: Once-daily dosing was studied directly in two of the cited trials; the original registration trials used twice-daily dosing. These are amounts documented in the cited studies and labels for Atomoxetine — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.

See the full reported protocol and its sources

Researched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.

Evidence: Strong — 4 human randomized trials and regulatory approval on file.
Evidence strengthStrong · 4/4
PreclinicalStrong human evidence

4 human randomized trials and regulatory approval on file.

Chemical structure of Atomoxetine (PubChem CID 54841)
Structure via PubChem

Quick answer

Atomoxetine, sold as Strattera, is a selective norepinephrine reuptake inhibitor approved for ADHD in children, adolescents and adults. It is not a stimulant and is not a controlled substance, so it carries no abuse potential and no immediate boost. Instead of working within an hour, its full effect typically builds over four to six weeks of continuous daily use.

Class
Selective norepinephrine reuptake inhibitor (non-stimulant)
Brand name
Strattera; also widely available as generic
Time to full effect
Usually 4–6 weeks of daily use
Controlled substance
No — unlike stimulant ADHD medicines
Common side effects
Appetite loss, nausea, fatigue, dry mouth, raised heart rate
Boxed warning
Suicidal ideation in children and adolescents; monitoring advised

Compiled by DoseRoutine from public sources including NIH/MedlinePlus, the FDA label, Mayo Clinic and PubChem. Educational information, not medical advice.

Plasma half-life
~5 h
Typical timing
in the morning
Default unit
mg

What published protocols report

Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.

Reported amounts
Adult ADHD trials titrated atomoxetine up to roughly 80–120 mg/day, most often reached via a starting dose near 40 mg/day[1][2][3][4]
Route studied
Oral capsule[1][2][3][4]
Frequency
Once-daily dosing was studied directly in two of the cited trials; the original registration trials used twice-daily dosing[1][2][3][4]
Cycle length
Trial durations ranged from about 10 weeks up to 24 weeks of continuous treatment[1][2][3][4]
Half-life
Reported as roughly 5 hours in typical metabolizers, considerably longer in poor CYP2D6 metabolizers[1][2][3][4]

Reported for Atomoxetine in the cited sources. Published ranges are not dosing advice.

References & evidence

Documents the Atomoxetine entry is written from. Each number matches an inline marker above.

  1. [1]Atomoxetine in adults with ADHD: two randomized, placebo-controlled studiesMichelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ · Biological Psychiatry · 2003 · Peer-reviewed · PMID 12547466
  2. [2]Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind, placebo-controlled trialYoung JL, Sarkis E, Qiao M, Wietecha L · Clinical Neuropharmacology · 2011 · Peer-reviewed · PMID 21406998
  3. [3]Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trialAdler LA, Spencer T, Brown TE, Holdnack J, Saylor K, Schuh K · Journal of Clinical Psychopharmacology · 2009 · Peer-reviewed · PMID 19142107
  4. [4]Efficacy and safety of atomoxetine hydrochloride in Korean adults with attention-deficit hyperactivity disorderLee SI, Song DH, Shin DW, Kim JH, Lee YS, Hwang JW · Asia-Pacific Psychiatry · 2014 · Peer-reviewed · PMID 25345739

References & Evidence

Sources on this page that document Atomoxetine dosing, timing and safety.

  1. [1]U.S. National Library of Medicine View source
  2. [2]National Center for Biotechnology Information View source

Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.

What is Atomoxetine?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.

Atomoxetine, marketed under the brand name Strattera, is a medication primarily used in the treatment of attention-deficit hyperactivity disorder (ADHD). Unlike many other ADHD medications, atomoxetine is a non-stimulant. It is approved for use in children, adolescents, and adults. Its action involves affecting specific neurochemicals in the brain, leading to improvements in attention span, hyperactivity, and impulsivity. As a non-controlled substance, it may be an option for individuals who do not respond well to stimulants or experience significant side effects from them, or for those with co-occurring conditions that preclude stimulant use. (Source: DrugBank, MedlinePlus)

What does the research say about Atomoxetine?

Tap a section to expand.

Atomoxetine is a selective norepinephrine reuptake inhibitor (SNRI). It works by blocking the reabsorption of norepinephrine, a neurotransmitter, back into the nerve cells. This action increases the concentration of norepinephrine in the synaptic cleft, the space between nerve cells in the brain. Norepinephrine plays a crucial role in attention, focus, impulsivity, and activity levels. By increasing its availability, atomoxetine helps to improve communication between brain cells involved in these functions, thereby alleviating the core symptoms of ADHD. The therapeutic effects of atomoxetine typically develop gradually over several weeks rather than immediately, as is common with stimulant medications. (Source: DrugBank, NIH)

Source for this section: Sources for How does Atomoxetine work?: Jumps to this entry in the sources and references list at the end of the page.

- **ADHD Symptom Management:** Atomoxetine helps to reduce key symptoms of ADHD, including inattention, hyperactivity, and impulsivity. This can lead to improved academic performance, social interactions, and daily functioning. - **Non-Stimulant Option:** For individuals who cannot tolerate or do not respond to stimulant medications, atomoxetine provides an alternative. It does not carry the same risk of abuse or dependence as stimulants, making it a suitable choice for some patient populations. - **24-Hour Coverage:** Due to its steady plasma concentrations, atomoxetine provides symptom control throughout the day and into the evening, which can be beneficial for consistent symptom management. (Source: FDA label, Mayo Clinic)

Numerous randomized controlled trials and meta-analyses support the efficacy of atomoxetine in treating ADHD across different age groups. For instance, studies published in peer-reviewed journals have demonstrated its effectiveness in reducing ADHD symptom severity scores compared to placebo in pediatric, adolescent, and adult populations. Long-term studies have also indicated sustained benefits. Research has also explored its use in individuals with comorbid conditions, such as anxiety disorders, where stimulants might be less suitable. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have approved atomoxetine for the treatment of ADHD based on extensive clinical trial data. (Source: Cochrane, FDA label, EMA SmPC)

Common side effects associated with atomoxetine include nausea, dry mouth, insomnia, decreased appetite, constipation, dizziness, and fatigue. In children and adolescents, stomach upset and decreased appetite are frequently reported. Less common but more serious side effects can include cardiovascular events (e.g., increased heart rate and blood pressure), liver problems, and suicidal ideation, particularly in children and adolescents during the initial weeks of treatment or dose changes. Priapism (a prolonged erection) is a rare but serious side effect. Any concerning or persistent side effects should be reported to a healthcare provider immediately. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.

Source for this section: Sources for What are the side effects of Atomoxetine?: Jumps to this entry in the sources and references list at the end of the page.

Atomoxetine carries a Boxed Warning regarding an increased risk of suicidal ideation in children and adolescents. Patients, their families, and caregivers should be vigilant for the emergence or worsening of depression, suicidal thoughts, or unusual changes in behavior. Cardiovascular effects, including increased blood pressure and heart rate, warrant careful monitoring, especially in individuals with pre-existing heart conditions or hypertension. Liver injury, though rare, has been reported, and patients should be monitored for signs such as dark urine, jaundice, or upper right quadrant tenderness. Before starting atomoxetine, a thorough medical history, including family history of heart disease and mental health conditions, should be taken. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.

Source for this section: Sources for Who should avoid Atomoxetine?: Jumps to this entry in the sources and references list at the end of the page.

Atomoxetine is contraindicated in individuals with known hypersensitivity to the drug or any of its components. It should not be used in patients with a history of pheochromocytoma or other serious cardiovascular disorders that could be worsened by increases in blood pressure or heart rate. Concomitant use with monoamine oxidase inhibitors (MAOIs) is contraindicated due to the risk of serious, potentially fatal reactions, including hyperthermia, rigidity, myoclonus, autonomic instability, and mental status changes, including extreme agitation progressing to delirium and coma. Atomoxetine should not be initiated within 14 days of discontinuing an MAOI, and MAOIs should not be initiated within 14 days of discontinuing atomoxetine. Patients with narrow-angle glaucoma should also avoid atomoxetine. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.

Source for this section: Sources for When should Atomoxetine not be taken?: Jumps to this entry in the sources and references list at the end of the page.

- **Monoamine Oxidase Inhibitors (MAOIs):** Concurrent use or use within 14 days of discontinuing an MAOI is strictly contraindicated due to the risk of severe and potentially fatal adverse reactions, including hypertensive crisis and serotonin syndrome. (Source: FDA label) - **CYP2D6 Inhibitors:** Medications that strongly inhibit the CYP2D6 enzyme (e.g., fluoxetine, paroxetine, quinidine) can significantly increase plasma concentrations of atomoxetine, potentially increasing the risk of side effects. Dose adjustments of atomoxetine may be necessary. (Source: DrugBank) - **Vasopressor Agents or Agents That Increase Blood Pressure:** Atomoxetine can increase blood pressure and heart rate. Caution is advised when co-administering with other medications that have similar effects, as this could exacerbate cardiovascular risks. (Source: FDA label) - **Beta-Agonists:** Co-administration with beta-agonists can potentially increase cardiovascular effects. (Source: EMA SmPC) This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.

Source for this section: Sources for What should you not mix with Atomoxetine?: Jumps to this entry in the sources and references list at the end of the page.

Atomoxetine is typically taken once or twice daily, with or without food. Given its half-life of approximately 5 hours (though some individuals may have a longer half-life due to genetic variations in CYP2D6 metabolism), a once-daily dose is often taken in the morning to provide sustained symptom control throughout the day. If a twice-daily regimen is prescribed, the doses are usually spaced to maintain consistent levels. The specific dose and administration schedule are user-directed and must be set by a licensed clinician. (Source: FDA label, DrugBank)

Source for this section: Sources for When should you take Atomoxetine?: Jumps to this entry in the sources and references list at the end of the page.

Put it into practice

Atomoxetine takes weeks of consistent daily dosing to show its full effect — a tracker with streaks and a journal makes that consistency far easier to keep.

What interacts with Atomoxetine?

Documented interactions for Atomoxetine: the other compound, the severity and confidence of the interaction, what happens, and what to do.
Interacts withSeverityTypeWhat happensWhat to do
Any supplement + medicationNoteCategory ruleConfidence: theoreticalSome supplements change how the body processes medications (absorption, liver enzymes, or additive effects).Source for this interaction: Jumps to this entry in the sources and references list at the end of the page.Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist.
Any vitamin + medicationNoteCategory ruleConfidence: theoreticalCertain vitamins interact with specific medications (e.g., vitamin K with blood thinners).Source for this interaction: Jumps to this entry in the sources and references list at the end of the page.Specific pairs are checked against a licensed source; confirm with your provider.

Frequently asked questions about Atomoxetine

Atomoxetine is primarily used to treat attention-deficit hyperactivity disorder (ADHD) in children, adolescents, and adults. It helps manage symptoms like inattention, hyperactivity, and impulsivity.

No, atomoxetine is a non-stimulant medication. It belongs to a class of drugs called selective norepinephrine reuptake inhibitors (SNRIs).

Unlike stimulant medications, the therapeutic effects of atomoxetine typically develop gradually over several weeks. Consistent daily use is necessary to achieve full benefits.

Yes, atomoxetine carries a Boxed Warning regarding an increased risk of suicidal ideation in children and adolescents, particularly during the initial weeks of treatment or dose adjustments. It is important to monitor for any changes in mood or behavior.

If a dose is missed, it should be taken as soon as remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule resumed. Do not take a double dose to make up for a missed one. Consult your clinician for specific guidance.

Interaction risk for Atomoxetine comes from the rest of the stack: other medications, prescription medicines, hormone therapy and peptides. Because Atomoxetine is usually taken in the morning, most avoidable conflicts come from what else lands in that same window. With a reported plasma half-life near 5 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Atomoxetine with no sign-up.

There is no single answer for Atomoxetine plus TRT. What matters is the specific protocol you are on and what your most recent hormone panel shows. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions

Pairing Atomoxetine with peptides has to be assessed one peptide at a time, because GLP-1 agonists, secretagogues, healing peptides and melanocortins do not share an interaction profile. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.

A short plasma half-life of roughly 5 hours is why protocols often split Atomoxetine across the day rather than using a single dose. It is typically taken in the morning. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps

For Atomoxetine the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.

Stimulants raise dopamine and norepinephrine and work within an hour, dose by dose. Atomoxetine works only on norepinephrine, builds over weeks, and covers the whole day rather than wearing off. It is often chosen where stimulants caused problems, where tics or anxiety complicate treatment, or where misuse risk is a concern. Average symptom improvement in head-to-head trials tends to be smaller than with stimulants. This is educational information, not medical advice.

Some effect may be noticed within one to two weeks, but the trials that established its benefit measured outcomes at four to six weeks, and a fair trial is usually considered at least six weeks at a stable amount. Judging it after a few days is the most common reason people stop it prematurely. This is educational information, not medical advice.

Reduced appetite is one of its most reported effects, and modest weight loss or slowed weight gain is seen especially early in treatment and in children, which is why growth is monitored. Appetite often partially recovers over months. It is not approved or appropriate as a weight-loss treatment. This is educational information, not medical advice.

Yes — those are common misspellings of atomoxetine, the non-stimulant ADHD medicine sold as Strattera. Pharmacy labels may also show it as atomoxetine hydrochloride, which is the salt form of the same molecule. This is educational information, not medical advice.

Atomoxetine is approved for adults as well as children and adolescents, and adult trials show reductions in inattention and impulsivity compared with placebo. Adults more often report dry mouth, nausea, insomnia and sexual side effects, and blood pressure and heart rate are usually checked during treatment. This is educational information, not medical advice.

Adult ADHD trials titrated atomoxetine up to roughly 80–120 mg/day, most often reached via a starting dose near 40 mg/day. Route reported: Oral capsule. Frequency reported: Once-daily dosing was studied directly in two of the cited trials; the original registration trials used twice-daily dosing. These are amounts documented in the cited studies and labels for Atomoxetine — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.

Sources cited on this page

Specific documents referenced by the numbered markers above. Each number matches the marker in the text.

  1. MedlinePlus(opens in a new tab)U.S. National Library of Medicine · medlineplus.gov/druginfo/meds/a603013.html
  2. PubChem CID 54840(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/54840

Verify at

Publisher search links for Atomoxetine. These are places to check the information — they are not citations, so they are not numbered.

DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.

What is the short answer on Atomoxetine?

Plain-text summary, safe to quote verbatim:

Atomoxetine, sold as Strattera, is a selective norepinephrine reuptake inhibitor approved for ADHD in children, adolescents and adults. It is typically taken in the morning. The reported plasma half-life is about 5 hours, which shapes dosing frequency. Dose, response, and interaction risk vary by individual, so use should be reviewed with a clinician.
Source: DoseRoutine — https://doseroutine.com/library/atomoxetine

Atomoxetine cheat sheet

DoseRoutine cheat sheet · Medication

Atomoxetine

Atomoxetine, sold as Strattera, is a selective norepinephrine reuptake inhibitor approved for ADHD in children, adolescents and adults. It is not a stimulant and is not a controlled substance, so it carries no abuse potential and no immediate boost.

Evidence

Strong

4 human randomized trials and regulatory approval on file.

Studied range

Adult ADHD trials titrated atomoxetine up to roughly 80–120 mg/day, most often reached via a starting dose near 40 mg/day

Route

Oral capsule

Frequency studied

Once-daily dosing was studied directly in two of the cited trials; the original registration trials used twice-daily dosing

Half-life

~5 h

Timing

in the morning

Prescription only (US)Approved by the FDA as Strattera for ADHD in children, adolescents, and adults, and carries a boxed warning about suicidal ideation in pediatric patientsNot a stimulant and not federally scheduled, unlike most other ADHD medications

Key references

  1. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies (2003)
  2. Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind, placebo-controlled trial (2011)
  3. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial (2009)

Studied ranges, not dosing advice. Not medical advice — talk to a clinician. doseroutine.com/library/atomoxetine

Cite this page

Using this in an article, AI answer, or research note? Please attribute:

DoseRoutine. (2026). Atomoxetine — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/atomoxetine
Canonical URL

What compounds are similar to Atomoxetine?

Others in the medication category or studied for the same goals.

Track Atomoxetine in DoseRoutine

Add it to your stack. We'll schedule doses, check interactions against everything else you take, and remind you at the right time.

Sign up free →

Latest research from DoseRoutine

Browse all DoseRoutine research updates

Track Atomoxetine in your own routine

Add Atomoxetine to your stack, get reminders at the right times, and see interaction notes with everything else you take. Free to start — no card needed.

Track Atomoxetine freeSign in